Amytril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amytril

Amytril (Amitriptyline): Quick Overview

Property Description
Active Ingredient Amitriptyline Hydrochloride
Form Oral tablets
Pharmacological Class Tricyclic Antidepressant (TCA)
Common Use (Primary) Major Depressive Disorder
Availability Prescription Only (Rx)

Amytril is a brand name for the generic prescription medication amitriptyline hydrochloride. It is classified as a first-generation tricyclic antidepressant (TCA). This class of drug works by affecting certain neurotransmitters in the central nervous system, particularly increasing the availability of serotonin and norepinephrine.

While initially approved in the 1960s for the treatment of major depressive disorder, amitriptyline is also clinically recognized for its use in managing various types of chronic pain and headaches. Due to its versatility and established track record, the drug is considered an essential medication in global healthcare.

A distinctive feature of amitriptyline is its strong sedative property and pronounced anticholinergic effects. These characteristics influence both its effectiveness in treating certain conditions, such as insomnia related to pain, and its potential side effect profile. It is commonly prescribed as an oral tablet and is available globally in various brand-name and generic formulations, requiring a prescription from a healthcare provider.

What side effects are possible with Amytril?

Amytril: Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Amytril (amitriptyline) using classifications based on frequency and affected System-Organ Classes.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions stem from the medicine's strong anticholinergic and sedative properties. These are classified in regulatory documents as Very Common (ge 1/10 people) and include dry mouth (xerostomia), drowsiness, dizziness, and constipation. Common (ge 1/100 people) effects include orthostatic hypotension (dizziness upon standing), tachycardia (rapid heartbeat), and weight gain.


Serious Safety Considerations

The label includes information on potential serious adverse reactions. A mandatory regulatory Boxed Warning highlights the increased risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (up to age 24), especially during the initiation of treatment and dosage adjustments. Other serious, though less frequent, documented concerns involve the Cardiac System, such as the potential for arrhythmias and QT interval prolongation, and the risk of precipitating an attack of Acute Angle-Closure Glaucoma.


Population-Specific Safety Notes

Official documents advise specific safety notes for certain patient populations. Older adults are documented to have increased susceptibility to adverse effects, particularly orthostatic hypotension and hyponatremia (low blood sodium). The medicine is also strictly contraindicated for use concurrently with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI), and during the acute recovery phase following a myocardial infarction.

Overdose and Emergency Response

Overdose with Amytril (amitriptyline) is documented by regulatory authorities as a severe, potentially life-threatening event requiring immediate medical intervention.

Documented Overdose Presentations

Overdose manifestations primarily affect the central nervous system (CNS) and the cardiovascular system. CNS effects may range from confusion, agitation, and seizures to profound stupor and coma. Cardiovascular toxicity is especially serious and includes severe hypotension, life-threatening arrhythmias (such as ventricular tachycardia and fibrillation), and ECG abnormalities like a prolonged QRS interval.

Anticholinergic signs, including hyperpyrexia (high body temperature), urinary retention, and mydriasis, are also officially documented.

Required Emergency Action

Regulatory agencies mandate that any suspected overdose requires the patient to seek immediate medical attention and contact emergency services without delay. Immediate hospitalization and specialized observation, including continuous cardiac monitoring, are required due to the risk of severe or delayed cardiotoxicity. No specific antidote is known for the drug’s overall toxicity profile, meaning management is strictly symptomatic and supportive. Interventions may include gastric decontamination and the use of sodium bicarbonate to manage cardiac electrical instability. Pediatric and elderly patients are noted as populations with increased sensitivity to acute toxicity.

Therapeutic Uses of Amytril

What Amytril Treats: Main Uses and Benefits

Amytril (amitriptyline) is commonly used across multiple therapeutic domains to help ease the overall symptom burden for patients. It is relevant in clinical settings for Major Depressive Disorder, where it supports the patient by assisting with the stabilization of mood and emotional distress. It is also considered relevant for easing symptoms related to persistent, chronic pain, particularly those involving heightened neurological activity like burning or shooting sensations associated with nerve damage, which create noticeable physiological strain.

The medication is applied across several key symptomatic domains, including conditions characterized by persistent depression, neuropathic pain, and is relevant for the prophylactic management of migraine headaches. Furthermore, due to its properties, it helps manage symptoms that interfere with daily comfort, such as sleep disruption secondary to pain or mood illness, which supports the patient during difficult episodes by easing distress. It is commonly used in scenarios where additional management of discomfort is required, especially when symptoms disrupt daily stability. Lastly, it may be part of symptomatic management for recurrent or episodic manifestations, assisting with maintaining functional stability when symptoms may intensify temporarily.

Therapeutic Focus: Neuropathic Pain Relief
Amytril is generally applied when managing long-standing nerve-related discomfort, helping to ease the intense, characteristic burning and shooting sensations.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility and Contraindications

Amytril (amitriptyline) use is defined by strict regulatory criteria concerning patient health status and age.

Absolute Contraindications (Must Not Use):

  • Patients with documented prior hypersensitivity to the drug.
  • Individuals in the acute recovery phase following a myocardial infarction (heart attack).
  • Patients concurrently receiving a Monoamine Oxidase Inhibitor (MAOI) or cisapride.

Age and Population Restrictions:

Population Regulatory Status
Adults Established eligible population.
Older Adults Eligible, but require cautious dose selection.
Adolescents (<18 years) Not recommended for general indications, as long-term safety is not established.
Children (ge6 years) Eligible only for the specific indication of Nocturnal Enuresis.

Conditional Use (Caution Required):

The medicine must be used with explicit caution in populations with pre-existing conditions, including severe cardiovascular disorders, a history of seizures, angle-closure glaucoma, urinary retention, and certain types of liver impairment.

Pregnancy and Lactation:

Use during pregnancy is conditional, permitted only if the potential benefit to the mother justifies the potential risk to the fetus. For lactation, a decision must be made to discontinue nursing or discontinue the medication.

What should I know about interactions with other medicines?

Amytril Interactions with other medicines and products

Official regulatory information classifies specific combinations with Amytril (amitriptyline) as either strictly contraindicated or requiring careful consideration due to documented changes in drug exposure or additive pharmacodynamic effects.

Contraindicated Combinations

The co-administration of Monoamine Oxidase Inhibitors (MAOIs), including agents like Linezolid and Intravenous Methylene Blue, is prohibited due to the risk of severe Serotonin Syndrome. Regulatory agencies mandate a 14-day separation period after discontinuing an MAOI before starting amitriptyline, and vice-versa. Additionally, co-administration with QTc-prolonging agents such as Cisapride and Pimozide is restricted, along with select antiarrhythmics, due to heightened risk of ventricular arrhythmia. The strong inhibitor Dronedarone is also contraindicated due to its effect on metabolism and drug transporters.

Pharmacokinetic and Pharmacodynamic Interactions

CYP2D6 inhibitors, including common selective serotonin reuptake inhibitors (SSRIs), are documented to reduce the metabolic clearance of amitriptyline, resulting in higher-than-expected plasma concentrations. This exposure modification is especially relevant for individuals classified as CYP2D6 Poor Metabolizers. Alcohol and other Central Nervous System (CNS) depressants are known to produce enhanced CNS depressant effects, which is a pharmacodynamic interaction. Furthermore, concurrent use with other serotonergic agents (e.g., Triptans, Tramadol) contributes to the documented risk of Serotonin Syndrome.

Mechanism of Action

Amytril (amitriptyline) modulates central nervous system neurotransmission primarily as a non-selective reuptake inhibitor of monoamines. It binds to the presynaptic norepinephrine transporter (NET) and the serotonin transporter (SERT), impeding the reabsorption of norepinephrine (NE) and serotonin (5-HT) back into the nerve terminals. This competitive blockade increases the concentration and residence time of NE and 5-HT within the synaptic cleft.

Downstream, this sustained elevation of monoamines activates post-synaptic receptors, leading to long-term adjustments in receptor sensitivity and intracellular signaling cascades. The drug also functions as an antagonist at several G-protein coupled receptors, including muscarinic cholinergic ( M1), histamine ( H1), and alpha-1 adrenergic (alpha1) receptors, which contributes to its overall physiological profile. Furthermore, amitriptyline exhibits voltage-gated sodium channel blockade in neuronal membranes, decreasing neuronal excitability, particularly within nociceptive pathways. System-level consequences include modulation of monoaminergic and cholinergic tone throughout the central and peripheral nervous systems.

Dosage and Administration Information

How to Use Amytril: Administration Guidelines

Amytril (amitriptyline) is administered by the oral route in tablet form, with usage governed by the principle of starting low and increasing the dose gradually (titration). Dosing schedules define both the starting amount and the maximum daily limit.

Feature Guideline
Route of Administration Oral tablet only.
Adult Starting Dose Typically 75 mg daily in divided doses, or 50 mg to 100 mg once daily at bedtime for depression; lower starting doses of 10 mg to 25 mg are common for indications like neuropathic pain.
Maintenance Range Usually 50 mg to 150 mg daily for outpatients, with higher doses up to 300 mg daily possible for severely ill hospitalized patients.
Timing & Frequency Dosing may be given once daily, often at bedtime or in the evening to account for the drug’s properties, or it may be divided throughout the day. It can be taken with or without food.
Tapering The medicine is withdrawn gradually over several weeks; abrupt cessation of treatment is generally not recommended.

Treatment is often continued for an appropriate duration, such as at least six months after recovery for Major Depressive Disorder, to help prevent a relapse. For certain populations, specific dosing considerations apply: older adults (over 65) or debilitated patients typically initiate treatment at the lower end of the adult dosing range, such as 10 mg to 25 mg daily, due to increased sensitivity.

Recent Clinical Evidence

Research evidence / Overview of studies for Amytril

Research has explored the use of Amytril across a range of conditions over several decades. The research base includes older randomized controlled trials (RCTs), alongside newer systematic reviews and meta-analyses, which contribute to the broader evidence landscape and help contextualize how patients reported their experience and how symptoms evolved in the observed populations. This summary focuses on the types of evidence available and the consistency of the data reported in authoritative sources.


Evidence for Major Depressive Disorder (MDD)

Research explored Amytril in numerous clinical trials for Major Depressive Disorder (MDD). Researchers utilized short-term RCTs, typically spanning 3 to 12 weeks, as well as subsequent systematic reviews. Studies monitored changes in the severity of depressive symptoms used in research exploring how symptoms change over time, often measuring outcomes related to systemic or functional imbalance using standardized scales.

While a large volume of research exists, the evidence is limited because many of the foundational trials are older and have variable quality, according to current standards of reporting. The certainty remains low for much of the evidence, and long-term effects are not fully established. High withdrawal rates among participants were observed in some studies, which can impact the interpretation of the short-term findings for the studied populations.


Evidence for Chronic Neuropathic Pain

The evidence base for conditions involving chronic neuropathic pain, such as painful diabetic neuropathy or postherpetic neuralgia, was explored in short-term randomized controlled trials, many of which used a cross-over design, alongside Cochrane Systematic Reviews. The primary outcomes studied for conditions where symptoms may vary in intensity were related to physical discomfort, specifically measuring pain intensity scores and patient-reported outcomes describing perceived discomfort.

However, the evidence is limited, and the certainty remains low in this area. A key limitation is that sample sizes were modest in many studies, meaning that the results apply only to the populations studied and may not be broadly generalizable. Furthermore, the follow-up durations were limited, providing limited information for long-term outcomes for conditions marked by functional limitations.


Evidence for Migraine Prevention

Amytril was evaluated in studies exploring the management of migraine headaches. Research examined outcomes reflecting daily functioning or activity level, specifically monitoring the change in the number of monthly migraine headache days over intermediate follow-up periods, typically between 16 and 26 weeks. The evidence contributes to the broader evidence landscape, and the research is often included in discussions of treatment approaches.

What is still uncertain is that relatively few large, modern, placebo-controlled trials have been conducted specifically for migraine prevention. Comparative evidence is lacking against the newest therapeutic classes.

Key Studies & References

  1. WHO Model List of Essential Medicines - Amitriptyline

Frequently Asked Questions (FAQ)

Common questions about Amytril (FAQ)


Q: Does Amytril interact with common pain relievers like ibuprofen?

Official documents state that pain relievers such as paracetamol or ibuprofen are generally allowed. However, caution is advised. Official guidance notes that combining Amytril with opioid-based medicines or other specific new medications requires monitoring by a healthcare provider, as some ingredients can increase the risk of side effects.


Q: Are there any specific foods or drinks to avoid while taking Amytril?

Regulatory information notes that alcohol intake should be avoided or limited, as it can significantly increase the sedating effects of the medicine. Some sources also suggest avoiding grapefruit juice, as observed data indicates it may lead to higher-than-expected levels of Amytril in the bloodstream.


Q: What is the evidence for using Amytril in long-term treatment?

According to official product information, for conditions like Major Depressive Disorder, treatment is typically continued for at least six months following the achievement of treatment goals. For indications such as neuropathic pain, therapy has been evaluated in some studies for periods extending to several years, but regulatory documents recommend that the appropriateness of continued use be regularly reassessed.


Q: Is Amytril commonly prescribed for children or older adults?

Regulatory information notes that older adults (over 65) are typically started on a lower dose due to increased sensitivity to the medicine’s effects. For children, the use of Amytril is generally reserved for the specific indication of nocturnal enuresis (bedwetting) in those aged six and older, as determined by a healthcare provider.


Q: Can Amytril interact with supplements like St. John's wort?

Yes, official safety information states that combining Amytril with herbal supplements like St. John's wort is generally contraindicated or advised against. This combination carries a risk of increasing serotonin levels in the body, which can lead to a serious condition called Serotonin Syndrome.


Q: Is it safe to drive or operate machinery while taking this medication?

Official documentation contains an explicit warning that driving or performing hazardous activities should be avoided until the patient knows how the medicine affects them. The medication has a risk of causing impaired coordination, reduced reaction time, and drowsiness.


Q: Does Amytril have any effect on sleep patterns?

Yes, the official product information reports that the medicine has a strong sedative property, which is why it is often administered in the evening. Documented side effects also include common drowsiness and less common reports of nightmares or general alterations in sleep patterns.


Q: How does Amytril work compared to SSRI medications?

Amytril is classified as a Tricyclic Antidepressant (TCA). This medicine affects two key chemical messengers: norepinephrine and serotonin. In contrast, Selective Serotonin Reuptake Inhibitors (SSRIs) primarily focus on blocking the reuptake of serotonin alone.


Q: Can Amytril cause changes to my vision?

Yes, the official documentation lists blurred vision and general changes in vision as reported side effects. Patients should also be aware of the more serious, though rare, risk of precipitating an attack of Acute Angle-Closure Glaucoma.


Q: Does Amytril interact with common over-the-counter cold medicines?

Official regulatory sources note that taking over-the-counter cold or allergy medicines with Amytril requires consultation with a healthcare provider. Certain ingredients, such as dextromethorphan (found in some cough syrups), can increase the risk of serious conditions like Serotonin Syndrome or heightened side effects.


Q: Is Amytril connected to any reports of withdrawal symptoms?

Yes, regulatory documentation mandates that the medicine be withdrawn gradually over several weeks. Abruptly stopping Amytril may lead to documented withdrawal-like symptoms, which can include nausea, headache, lack of energy, and feeling restless, which is why official information mandates that the medicine be withdrawn gradually.


Q: What should I know about the safety of Amytril for people with liver or kidney issues?

Official documentation states that the medicine must be used with explicit caution in patients with severe liver impairment and those with a history of liver disease. However, for people with reduced renal function (kidney issues), the medicinal product can typically be administered using the usual dose guidelines.


Q: What is the main difference between Amytril and other similar medicines?

Amytril belongs to the Tricyclic Antidepressant (TCA) class, which is chemically characterized by a three-ring structure. Its pharmacological difference is based on its action on multiple neurotransmitters (serotonin and norepinephrine) and its strong antagonistic effects on several other receptors.


Q: How quickly can someone expect to feel the effects of Amytril?

According to official product information, improvement in symptoms of depression has been observed in study data, typically noted after 2–4 weeks of consistent treatment. For conditions like chronic pain, the maximum observed response in studies may take longer, often between 4–6 weeks, although patients may report improvements in sleep sooner.


Q: Is Amytril a controlled substance or addictive?

Regulatory agencies do not classify Amytril as a controlled substance. Furthermore, the medicine is not considered addictive, but abruptly stopping treatment can cause withdrawal-like symptoms, which is why a gradual reduction is advised.


Q: Can Amytril affect memory or concentration?

Official safety information indicates that symptoms such as confusion and problems concentrating have been reported, particularly in cases of overdose. The medicine's mechanism of action includes anticholinergic properties, which can sometimes lead to cognitive effects like confusion.


Q: Do studies show that Amytril works better than no treatment at all?

Reviews of clinical trial data indicate that Amytril has shown a small difference in effect on depression when compared to placebo in studied populations. The official literature notes that the observed difference in effect is sometimes difficult to fully determine in older trials due to the medicine's side effects potentially making blinding difficult.


Q: What are the signs that Amytril might not be working for a person?

The official regulatory label notes that a change in treatment may be considered by a healthcare provider if the patient’s condition, such as depression, is persistently worsening. This includes the emergence of symptoms like suicidality or other behaviors considered precursors to clinical decline.


Q: What kind of monitoring is usually required when taking Amytril?

Official regulatory information recommends performing an ECG (electrocardiogram) prior to initiating therapy to rule out certain pre-existing heart conditions. Additionally, close observation and monitoring for clinical worsening, suicidality, and unusual changes in behavior are required, especially at the start of treatment.


Q: Is Amytril known to cause any sexual side effects?

Yes, the official product information reports that the medication may cause documented side effects, including changes in sex drive or ability. These effects are typically reviewed by a healthcare provider.


Q: Is it normal to feel a bit restless when starting Amytril?

Yes, the official prescribing information notes that restlessness (psychomotor restlessness or akathisia) has been reported in patients. This symptom is most likely to occur at the beginning of drug therapy or following an adjustment in the dose.


Q: What does it mean if the medicine is described as a 'tricyclic'?

The classification "Tricyclic Antidepressant" (TCA) refers to the characteristic three-ring structure found in the chemical backbone of the active ingredient, amitriptyline. This specific chemical structure defines its pharmacological class.


Q: How long does Amytril stay in your system after stopping treatment?

The exact time the medicine fully clears the system can vary by individual. However, regulatory agencies require a minimum of 14 days to elapse after stopping Amytril before starting other medications, such as Monoamine Oxidase Inhibitors (MAOIs), to ensure the drug has fully cleared the body.


Q: What are the risks of taking Amytril with herbal teas?

Official cautions advise against combining Amytril with herbal products that have serotonergic activity or that affect the body's liver enzymes, which may be ingredients in certain herbal teas. The supplement St. John's wort is specifically contraindicated.


Q: Is there a maximum length of time Amytril can be taken?

Official regulatory information does not define a maximum duration of therapy. While a minimum period of at least six months is common for depression, treatment for certain conditions, such as chronic pain, may continue for several years under regular medical reassessment.


Q: What are the common reasons people discontinue taking Amytril?

Reviews of clinical trial data indicate that Amytril had a higher rate of patient discontinuation than placebo, primarily due to adverse effects. The most common reasons for discontinuation in studies are typically related to the frequently reported side effects, such as dry mouth, drowsiness, or weight gain.

How should Amytril be stored and disposed of?

How to Store and Dispose of Amitriptyline (Amytril)

Official regulatory guidelines define strict conditions for the storage and disposal of amitriptyline tablets to ensure stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), defined as Controlled Room Temperature.
Container/Light Must be dispensed and stored in a tight, light-resistant container.
Child Safety KEEP OUT OF THE REACH OF CHILDREN is mandatory.

Disposal Instructions

Disposal of unused or expired tablets should prioritize drug take-back programs or community mail-back envelopes. If these options are unavailable, the medicine can be discarded in household trash by mixing it with an undesirable substance (such as dirt or coffee grounds) and placing the mixture in a sealed container. Amitriptyline is not recommended for disposal by flushing down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amytril found in:

A-Z Index: